Provider notes

• NMUH:
  
  • No restriction stated (not Galfer)
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Oral syrup available as 140 mg/5mL
• UCLH:
• WH:
  • Oral syrup available as 140 mg/5mL (ONLY formulation available)

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • Ferrous gluconate contains a lower content of elemental iron and therefore may be better tolerated than ferrous sulphate.

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  
  • First choice for iron-deficiency anaemia
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
• No restriction stated
• RFL:
• Non-formulary
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • Neonatal/paediatrics only

Provider notes

• NMUH:
• No restriction stated
• RFL:
• No restriction stated
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

See local guidance for iron replacement

Approved for:

1. Iron deficient anaemia in Obstetrics (January 2017)
2. Iron deficient anaemia in adult outpatients only, not in patients in first trimester of pregnancy or for patient on haemodialysis (March 2017)

Provider notes

• NMUH:
  
  • To be used for day case patients and out patients ONLY
  • See link below for parenteral irons prescribing guideline.
  • Ferinject must be prescribed on the specific Daycase Ferinject prescription form; see link below
  • Note: Parenteral iron is contraindicated in the first trimester of pregnancy. For dose of Ferinject in patients with haemodialysis dependent chronic kidney disease, refer to the summary of prouct characteristics.
  • Check MHRA Drug Safety updates
• RFL:
  • Approved for use in private patients at RFL
  • Approved for use in renal and liver patients at RFH
• RNOH:
  • For the optimisation of pre-operative anaemia in patients aged 14 to 17 years.
• UCLH:
  • Restricted to outpatients / daycase / facilitate inpatient discharge
• WH:
  • Parenteral iron should only be considered if oral therapy has failed due to lack of patient co-operation, severe gastrointestinal side effects, continuing severe blood loss or malabsorption. Provided oral therapy is taken reliably and is absorbed, then the haemoglobin response is not significantly faster with the parenteral route.

See local guidance for iron replacement

Provider notes

• NMUH:
• Check MHRA Drug Safety update
• RFL:
• First-choice of fast infusion product (excluding renal)
• Available to all patient groups at BH and CFH.
• Restricted to specific patient groups at RFH:
  • For patients who would otherwise require multiple iron infusions, and there is a documented reason why multiple infusions would impact on patient’s quality of life
  • For patients on 2NA in whom a shorter duration iron infusion is indicated, and there is documented reason why a longer infusion would impact on patient’s quality of life
  • For patients in whom there is an URGENT need for IV iron e.g. patients planned for Theatre, or for pregnancy
  • For patients on a cancer pathway to enable cancer treatment to proceed
  • For patients with disabling anaemia who require urgent correction of Hb levels, based on clinical symptoms/clinical need (patient-specific need)
  • For patients who have experienced serious / life-threatening allergies or adverse events to other IV iron products
• RNOH:
• For the optimisation of pre-operative anaemia in accordance with local guideline. Oral iron must be used where surgery is not urgent
• UCLH:
• WH:
• Non-formulary

See local guidance for iron replacement

Provider notes

• NMUH:
  • See link below to access the Trust guidelines on use of parenteral irons for iron deficiency anaemia
  • Check MHRA Drug Safety updates
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary 

See local guidance for iron replacement

Provider notes

• NMUH:
  • See Trust guidelines on use of parenteral irons for iron deficiency anaemia; link below
  • Check MHRA Drug Safety updates
• RFL:
  • Renal anaemia only - Venofer and Cosmofer are preferred choices
• RNOH:
  • Preferred parenteral iron preparation for inpatients
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
  • When used in combination with oral methotrexate various regimens are used from once-weekly, twice-weekly to daily use (except on day of methotrexate)
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • Folic acid is indicated in confirmed folate deficiency due to dietary lack, gastrointestinal disease, pregnancy, chronic haemolytic states, myeloproliferative disorders, haemodialysis, and parenteral nutrition, intensive care of the very sick patient or in premature infants. Folic acid can be used to correct serious haematological changes caused by dihydrofolate reductase inhibitors (DFRIs), after the DFRI has been discontinued. Examples of DFRIs include trimethoprim and co-trimoxazole.
  • Before treating megaloblastic anaemia with folic acid alone, vitamin B12 deficiency MUST be excluded. Folic acid may relieve the haematological features of vitamin B12 deficiency and allow neuropathy to develop undetected. If treatment must be started immediately, both folic acid and hydroxocobalamin should be given.

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
• Non-formulary
• RFL:
• As per NICE
• RNOH:
• Non-formulary
• UCLH:
• See links below
• WH:
• Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  
  • Hydroxycarbamide Suspension 50mg/5ml (100 ml) unlicensed preparation is also available
• RFL:
  
  • Restricted to Haematology
  • Not prescribed on Chemocare for this indication
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
• RFL:
  
  • Restricted to Renal team – preferred brand of erythropoietin
  • Restricted to Haematology for MDS
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • As per NICE TA 323

Provider notes

• NMUH:
• For anaemia associated with chronic renal failure only.
• Restricted to renal consultants signature and Dr. Tindall signature only.
• Please note that the CSM has advised that the subcutaneous route is contraindicated in chronic renal failure. Please use the IV route instead. The dialysis unit has changed over to NeoRecormon which is an IV preparation.
• RFL:
• Restricted to Renal team - for patients who cannot tolerate darbepoetin or established patients only
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Epoetin is available for treatment anaemia of renal disease only

Provider notes

• NMUH:
  
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • Restricted to Renal and Haematology Consultants.
  • See MHRA drug safety updates 
• RFL:
  
  • Restricted to Renal team - for patients who cannot tolerate darbepoetin or established patients only
  • Restricted to Haematology for MDS
• RNOH:
  
  • Store in a refrigerator
• UCLH:
• WH:
  
  • Epoetin is available for treatment anaemia of renal disease only
  • Pre-filled syringe 2,000 units, 3,000 units, 4,000 units, 6,000 units, 10,000 units ONLY

Provider notes

• NMUH:
  
  • Non-formulary.
• RFL:
  
  • Restricted to renal team only - for patients who cannot tolerate darbepoetin or established patients only
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  • See links below
• RFL:
  • Commissioned as per NHS England policy for haemoglobinopathies.
  • Confirm with the commissioning team regarding other indications.
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  •  To be prescribed by the Haematology Team ONLY.
  • See links below
• RFL:
  
  • Commissioned as per NHS England policy for haemoglobinopathies.
  • Confirm with the commissioning team regarding other indications.
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Tabs 500 mg ONLY

Provider notes

• NMUH:
  • To be prescribed by the Haematology Team ONLY.
  • See links below
• RFL:
  • Commissioned as per NHS England policy for haemoglobinopathies.
  • Confirm with the commissioning team regarding other indications.
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

See NICE TA for eligibility criteria

Provider notes

• NMUH: 
  • As per NICE TA626 
• RFL: 
  • Non-formulary 
• RNOH: 
  • Non-formulary 
• UCLH: 
• WH: 
  • Non-formulary 

Provider notes

• NMUH:
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines see link below.
• RFL:
  • As per NICE guidance and CCG policy
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • See links below

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • As per NICE TA 617

Provider notes

• NMUH:
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
• RFL:
  • As per NICE guidance and CCG policy
• RNOH:
  • Non-formulary
• UCLH:
• WH    approvals:
  • As per NICE TA 221

Provider notes

• NMUH:
  • Zarzio^® is the preferred brand
  • Check MHRA Drugs Safety Alerts
  • See link below
• RFL:
  • Accofil^® is the preferred brand (from June 2019)
• RNOH:
  • Requires HAEMATOLOGIST approval
  • Store in a refrigerator
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • Restricted for use in paediatric patients ONLY. For Adult patients, use filgrastim (Zarzio) first line.
• RFL:
  • Non-formulary
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Alternative to GCSF + district nurse administration at WH only for patients who can receive daily GCSF but cannot self-inject (JFC August 2016)

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • For use by oncology consultants only in patients unable to receive daily GCSF infections or needle phobic patients (D&TC Sept 2016)

Provider notes

• NMUH:
  • See link below
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • See link below
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • Effervescent potassium is preferred to the modified release preparation as it is associated with less risk of oesophageal ulceration. Effervescent potassium can be administered via a nasogastric tube.

Provider notes

• NMUH:
  • See link below
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • Effervescent potassium is preferred to the modified release preparation as it is associated with less risk of oesophageal ulceration. Effervescent potassium can be administered via a nasogastric tube.

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• As per NICE TA623
• RFL:
• Non-formulary
• RNOH:
• Non-formulary
• UCLH:
• WH:
• As per NICE TA623

Provider notes

• NMUH:
  • The rectal route should be reserved for patients who are vomiting or have upper gastrointestinal tract problems, including paralytic ileus or it may be used simultaneously with the oral route for more rapid initial results.
  • See BNF for instructions on administration. Please consult product literature for further information.
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • 'Calcium Resonium' exchanges potassium ions for calcium ions. It should be avoided in patients with hypercalcaemia, as it further raises calcium levels.
  • Adult dose:
    • Oral: 15 g PO 6 to 8 hourly in water (not fruit juice which has a high K+ content)
    • Rectal: 30g once daily. Made by adding 30g of Calcium Resonium resin to 200ml Methylcellulose 1% solution. The retention enema is left in situ for 9 hours. Although rectal administration may be useful vomiting is a problem, the oral preparation may be preferred by some patients despite some nausea.
  • In initial stages, Calcium Resonium may be given both rectally and orally to achieve a more rapid lowering of serum potassium. Administration should be stopped once potassium reaches 5.0 mmol/L. Onset of action is between 2 and 12 hours.

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • 'Resonium A' exchanges potassium ions for sodium. It should be avoided in patients with congestive heart failure, water and salt overload, hypertension or where dietary sodium content is medically restricted.

See NICE TA for eligibility criteria

Provider notes

• NMUH:
• As per NICE TA599
• See Management of hyperkalaemia guideline
• RFL:
• Non-formulary
• RNOH:
• As per NICE TA599
• UCLH:
• WH:
• As per NICE TA

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  
  • St. Marks’ Solution is not kept at NMUH but all ingredients are available individually (i.e. sodium chloride, sodium bicarbonate and anhydrous glucose).
• RFL:
  
  • St. Marks’ Solution is not kept at RFL but all ingredients are available individually (i.e. sodium chloride, sodium bicarbonate and anhydrous glucose).
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • WHO Oral Rehydration Powder is not kept at RFL but all ingredients are available individually (i.e. sodium chloride, potassium chloride, sodium citrate and anhydrous glucose).
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  • Oral solution - unlicensed preparation, (5mmol / 5mL) also available for correction of acidosis in paediatric patients
• RFL:
  • 500mg capsules and 1mmol/mL oral solution stocked
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • The use of sodium bicarbonate capsules is restricted to the Renal team only. Caps 500 mg containing approximately 6 mmol of Na+ and HCO3-

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Only use if Hartmann’s is unavailable
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  
  • Sodium chloride 0.18% and glucose 4% (500 mL)
  • Sodium chloride 0.45% and glucose 5% (500 mL)
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  
  • Sodium chloride 0.9% (10 mL, 100 mL, 250 mL, 500 mL and 1000 mL)
  • Sodium chloride 0.45% (500 mL)
  • Sodium chloride 2.7% (500 mL)
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  • Glucose 5% (100 mL, 250 mL, 500 mL and 1000 mL)
  • Glucose 10% (500 mL)
  • Glucose 20% (500 mL)
  • Glucose 50% (50 mL)
  • Glucose 1% in compound sodium lactate (Hartmann's) (1000 mL)
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • Administer according to IV Potassium Policy
• RNOH:
  
  • Potassium chloride 0.15% and glucose 5% (1000 mL)
  • Potassium chloride 0.30% and glucose 5% (1000 mL)
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • Administer according to IV Potassium Policy
• RNOH:
  
  • Potassium chloride 0.15%, sodium chloride 0.18% and glucose 4% (1000 mL)
  • Potassium chloride 0.30%, sodium chloride 0.18% and glucose 4% (1000 mL)
  • Potassium chloride 0.15%, sodium chloride 0.45% and glucose 5% (500 mL) - for use by ADU/Coxen and CHDU
  • Potassium chloride 10mmol with sodium chloride 0.9% and glucose 5% is no longer available. An equivalent fluid can be prepared by adding 50 ml of 50% glucose to 500 mL potassium chloride 0.15% and sodium chloride 0.9%
• UCLH:
• WH:
  
  • Infusion 500 ml (15 mmol Na+ and 10 mmol K+, 80 kcal)
  • Infusion 1000 ml (30 mmol Na+ and 20 mmol K+, 160 kcal

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • Administer according to IV Potassium Policy
• RNOH:
  
  • Potassium chloride 0.15% and sodium chloride 0.9% (500 mL and 1000 mL)
  • Potassium chloride 0.30% and sodium chloride 0.9% (500 mL and 1000 mL)
  • Unlicensed: Potassium Chloride 3% in Sodium Chloride 0.9% Intravenous Infusion (40 mmol in 100 mL). Must be ordered and stored as a Controlled Drug. Restricted to ITU only.
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • Restricted to NICU and Renal Dialysis Wards (for addition to dialysis fluids bags only)
  • Must be ordered and stored as a controlled drug. 
  • Administer according to IV Potassium Policy
• RNOH:
  
  • Must be ordered and stored as a Controlled Drug. Restricted to ITU, Theatres and Recovery only
• UCLH:
• WH:
  
  • The ready-made potassium solutions should cover most requirements and should be used in preference to the strong injection.

Provider notes

• NMUH:
• Restricted to ICU
• Administer according to IV Potassium Policy
• RFL:
• Restricted to ICU and Cardiac Resuscitation Trolleys only
• Administer according to IV Potassium Policy
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • 500 mL and 1000 mL
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • 1.26%, 2.74%, 4.2% and 8.4% polyfusor 500mL
• RNOH:
  
  • 8.4%: 10 mL, 100 mL and 200 mL Polyfusor
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • No restriction stated
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • 10 mL
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • Available as 500 mL and 1000 mL bottles or 1000 mL and 3000 mL bags
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Available via the blood bank
• RNOH:
  • Available from Pathology
• UCH approvals:
• WH:
  • No restriction stated

Provider notes

• NMUH:
• Non-formulary
• RFL:
• BCF: No restriction stated
• RFH: Non-formulary
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • BCF: Non-formulary
  • RFH: No restriction stated
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • Non-formulary
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
  
  • Restricted to Barnet ICU
• RNOH:
• Non-formulary
• UCLH:
• Non-formulary
• WH:
• Non-formulary

Provider notes

• RFL:
  • Contact Nutrition team for advice

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • Non-formulary
• RNOH:
  
  • For patients requiring effervescent calcium carbonate
• UCLH:
•  WH:
  
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • BCF: No restriction (historical)
  • RFH: Non-formulary
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Approved for complex primary hyperparathyroidism in adults in line with NHSE clinical commissioning policy (JFC April 2018)

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
  • Formulary for treatment of Hypercalcaemia of primary hyperparathyroidism or parathyroid carcinoma - see link below
• RFL:
  
  • Restricted to ‘cinacalcet gatekeeper’ approval only for secondary hyperparathyroidism – see NICE TA.
  • Restricted to endocrinology for complex primary hyperparathyroidism – see NHSE commissioning policy
• RNOH:
  
  • Non-formulary
• WH:
  
  • For primary hyperparathyroidism in line with NHSE policy 16034/P
  • For secondary hyperparathyroidism in line with NICE TA 117

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to ‘etelcalcetide gatekeeper’ approval only for secondary hyperparathyroidism – see NICE TA
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Approved for percutaneous injection into the parathyroid gland for hyperparathyroidism if intolerant or unresponsive to oral therapy (November 2013)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Approved for magnesium deficiency (JFC March 2017)

Provider notes

• NMUH:
  
  • See link below to access Trust Formulary bulletin on oral Magnesium Aspartate
• RFL:
  
  • Non-formulary
• RNOH:
  
  • For patients requiring enteral administration i.e. NG/PEG admin or with swallowing difficulties
• UCLH:
  
  • Second line to NeoMag®
• WH:
  
  • First line treatment for hypomagnesaemia (approved by NCL JCF Mar17). Magnesium glycerophosphate only for patients unable to tolerate magnesium aspartate.

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • The BNF states that to prevent recurrence of hypomagnesaemia in adults, oral magnesium may be given in a dose of 24 mmol Mg2+ daily in divided doses. In children aged 1 month to 12 years, the BNF for children recommends that the initial dose of oral magnesium for hypomagnesaemia is 0.2 mmol/kg Mg2+ three times daily, with the dose adjusted as needed. In children aged 12 to 18 years, it recommends that the initial dose is 4 to 8 mmol Mg2+ three times daily, adjusted as needed.
• UCLH:
• WH:
  • First line treatment for hypomagnesemia is magnesium aspartate. Magnesium glycerophosphate should only be used for patients unable to tolerate magnesium aspartate.

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • BCF: No restriction (historical)
  • RFH: Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • Only magnesium sulphate 50% injection stocked
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • The use of magnesium sulphate inj 10% & 20% are restricted to Obstetrics only.

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Renal tubular disorders outpatients clinic only (RFL only; JFC September 2018)
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
• For the treatment of hypophosphataemia or premature bone disease in paediatric patients. For further prescribing information, refer to the BNF for Children. 
• RFL:
• For neonates & paediatrics
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to renal patients only
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • Restricted to renal patients only
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • Non-formulary
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  
  • Calcichew is available on the Formulary for the management of hyperphosphotaemia in renal patients
• RFL:
  
  • No restriction stated
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Restricted to renal patients only
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  
  • Restricted to renal patients only
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • Restricted to renal patients only - not preferred – use sevelamer carbonate preferentially
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Non-formulary
• RNOH:
• Non-formulary
• UCLH:
• WH:
• 0.619% toothpaste available for Simmons House and Islington community clinics only 

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • For Islington community only

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • For Islington Community Only - direct ward delivery

Provider notes

• NMUH:
  
  • Only to be used where there is good evidence of deficiency. Therapy to be discontinued when clinical improvement occurs.
• RFL:
  
  • No restriction stated
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • No restriction stated
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • For community clinics only

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • Only the 50mg tablets kept at the RFH
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

 Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Non-formulary
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • Tablets 50mg,100mg, 200mg and 500mg
  • Injection 500mg
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • See link below
• RFL:
  • No restriction stated
• RNOH:
  • Store in refrigerator
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • See link below
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • See links below
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • See links below
• RFL:
  • No restriction stated
• RNOH:
  • Oral liquid available as 3000 units/mL
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • 300,000 units intramuscular injection only
• RNOH:
  
  • Restricted
• UCLH:
• WH:
  
  • Inj 7.5 mg (300,000 units)/1 ml only

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • Oral suspension and injection 100mg/2ml kept at the RFH.
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
• No restriction stated
• RFL:
• No restriction stated
• RNOH:
• 10 mg tablets stored in the EDC
• UCLH:
• WH:
• No restriction stated

Provider notes

• NMUH:
• No restriction stated
• RFL:
• No restriction stated
• RNOH:
• Can be given undiluted by slow intravenous injection over at least 30 seconds - see Medusa Injectable Medicines Guide for further information
• UCLH:
• WH:
• Konakion MM may be administered by slow intravenous injection, or by intravenous infusion in glucose 5%, at a rate of not less than 1 mg/minute. It is currently unlicensed for use by intramuscular injection, although it can be given by this route on the prescriber’s responsibility.

Provider notes

• NMUH:
• No restriction stated
• RFL:
• No restriction stated
• RNOH:
• Konakion MM Paediatric can be administered by intramuscular or intravenous injection or by oral administration depending on the indication - see the SPC for further information
• UCLH:
• WH:
• This is the only vitamin K preparation licensed for oral administration. As an alternative there is Phytomenadione 20 mg/ml oral drops (unlicensed).

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Non-formulary
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Please note that this preparation is NOT LICENSED for use in the UK

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
• No restriction stated
• RFL:
• No restriction stated
• RNOH:
• No restriction stated
• UCLH:
• WH:
• Discharge prescribing for neonates only

Provider notes

• NMUH:
• No restriction stated
• RFL:
• No restriction stated
• RNOH:
• No restriction stated
• UCLH:
• WH:
• No restriction stated

Approved for vitamin deficiency in chronic kidney disease (April 2015)

Provider notes

• NMUH:
  
  • For continuation of treatment. Initiation by the renal team ONLY.
• RFL:
  
  • Preferred multivitamin for CKD - renal team only
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • No restriction stated

Approved for the dietary management of patients with cystic fibrosis on the specific recommendation of a specialist in cystic fibrosis; available as capsules ("Softcaps"), chewable tablets ("Chewables") and liquid ("Liquid") (JFC September 2018).

Provider notes

• NMUH:
  
  • For continuation only. Not stocked but ordered in if patient admitted on supplement as per indication stated above
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Initiation as above only

 (hospital only prescribing) for refeeding syndrome

for other indications

Approved for prophylaxis of refeeding syndrome (JFC October 2018)

Provider notes

• NMUH:
• For refeeding syndrome ONLY - refer to Trust Guideline
• RFL:
• Non-formulary
• RNOH:
• No restriction stated
• UCLH:
• WH:
• Refeeding syndrome only

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Non-formulary
• RNOH:
• No restriction stated
• UCLH:
• WH:
• No restriction stated

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Not preferred – use Renavit preferentially for CKD - renal team only
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

See NICE HST for eligibility criteria

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Gaucher disease in line with NICE HST
• RNOH:
• Non-formulary
• UCLH:
• Gaucher disease in line with NICE HST
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • Non-formulary
• RNOH:
  
  • Non-formulary
• UCLH:
  
  • Primary mitochondrial deficiency in patients with confirmed mitochondrial defect or defined respiratory chain deficiency (August 2016)
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to paediatrics and neonates
• RNOH:
• Non-formulary
• UCLH:
• WH:
• No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted for Wilson’s specialist use only
• See NHSE clinical commissioning policy
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • No restriction stated
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • Non-formulary for paediatrics (GOSH specialist service)
  • For peritoneal dialysis patients (levocarnitine deficiency)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
  • Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE HST for eligibility criteria

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Morquio A Syndrome in line with NICE HST
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

See NICE HST for eligibility criteria

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Fabry disease in line with NICE HST
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to the lysosomal storage disorders unit
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Restricted to renal team
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• For peritoneal dialysis patients only (arginine deficiency)
• Non-formulary for other indications (inc. paediatrics)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Non-formulary (inc. paediatrics)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
• Non-formulary
• RFL:
• No restriction stated
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
• RFL:
• Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
• RNOH:
• Non-formulary
• UCLH:
• WH:

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
• RFL:
• Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
• RNOH:
• Non-formulary
• UCLH:
• WH:

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
• RFL:
• Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
• RNOH:
• Non-formulary
• UCLH:
• WH:

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
• RFL:
• Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
• RNOH:
• Non-formulary
• UCLH:
• WH:

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for 2^nd line management of Delayed Haemolytic Transfusion Reactions [DHTRs] hyperhaemolysis in adult Sickle Cell and β-thalassaemia patients who have not responded to IVIG and steroids (pending internal funding approval; JFC July 2019)

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Non-formulary
• RNOH:
• Non-formulary
• UCLH:
  • Restricted to haematology. UMC to be informed of each patient. Funding agreed for 1 patient per annum. 
• WH:
• Non-formulary